Table 3 Thromboembolic events.
From: Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
GSK3368715 dosea | Primary neoplasm at diagnosis | Thromboembolic event | Grade | Anticoagulation status | |
|---|---|---|---|---|---|
Started prior to study treatment | Stated medication(s) | ||||
50 mg | Cholangiocarcinoma | Portal vein thrombosis | 2 | Not known | Not known |
100 mg | Pancreas adenocarcinoma | Pulmonary embolism | 3 | No | Enoxaparin 40 mg QD intramuscularly |
Head and neck squamous cell carcinoma | Pulmonary embolismb | 2 | No | Bemiparin 7500 units intradermally | |
200 mg | Pancreas adenocarcinoma mucinous | Pulmonary embolismc | 5 | No | Heparin 25,000 units continuous infusion Enoxaparin sodium 60 mg BID subcutaneously Rivaroxaban 15 mg QD oral |
Colon/rectum adenocarcinoma | Portal vein thrombosis Pulmonary embolism | 3 3 | No | Enoxaparin sodium 60 mg BID subcutaneously | |
NSCLC adenocarcinoma | Aortic thrombosisd,e Portal vein thrombosis | 3 3 | No | Enoxaparin sodium 60 mg BID subcutaneously | |
Mucoepidermoid carcinoma of parotid | Pulmonary embolism | 3 | No | Enoxaparin sodium 60 mg BID subcutaneously edoxaban 60 mg QD oral | |
Epithelioid hemangioendothelioma | Pulmonary embolism | 3 | No | Enoxaparin sodium 60 mg BID subcutaneously Rivaroxaban 15 mg QD oral | |
Prostate adenocarcinoma | Deep vein thrombosisd,e Pulmonary embolism | 3 3 | No | Enoxaparin sodium QD subcutaneously Rivaroxaban 15 mg QD oral | |
